{"id":928588,"date":"2026-01-20T11:46:58","date_gmt":"2026-01-20T16:46:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/"},"modified":"2026-01-20T11:46:58","modified_gmt":"2026-01-20T16:46:58","slug":"cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/","title":{"rendered":"Cogent Biosciences to Initiate New Drug Application (NDA)\u00a0Submission for\u00a0Bezuclastinib Under\u00a0Real-Time Oncology Review (RTOR)\u00a0"},"content":{"rendered":"
\n

\n –\u00a0 PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and ORR of 46% in patients who had received prior treatment with imatinib\u00a0<\/em>
\n \n <\/p>\n

\n –\u00a0 Cogent is expected to\u00a0initiate\u00a0the RTOR process\u00a0immediately;\u00a0completion of the PEAK NDA\u00a0submission expected in April 2026<\/em>\n <\/p>\n

WALTHAM, Mass. and BOULDER, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc.<\/a>\u202f(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has agreed to accept its New Drug Application (NDA) for bezuclastinib in combination with sunitinib for patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with imatinib under the Real-Time Oncology Review (RTOR) program.\u00a0<\/p>\n

\u201cThis milestone reflects the FDA\u2019s recognition of the significant unmet need facing patients with imatinib resistant GIST,\u201d said Andrew Robbins, Cogent\u2019s President and Chief Executive Officer. \u201cBased on positive results from the PEAK trial, the bezuclastinib combination has the potential to be the first new approval in this patient population in over 20 years. We look forward to the continued, close collaboration with the FDA as we advance bezuclastinib toward commercialization.\u201d\u00a0<\/p>\n

As announced in November 2025, the bezuclastinib combination in the PEAK trial demonstrated a substantial and highly statistically significant clinical benefit on the primary endpoint of progression free survival (PFS), reducing risk of disease progression or death compared to the current standard of care by 50% (hazard ratio of 0.50, 95% CI: 0.39 \u2013 0.65). mPFS, as assessed by blinded independent central review, was 16.5 months for the bezuclastinib combination vs. 9.2 months for sunitinib monotherapy. Additionally, the bezuclastinib combination demonstrated an unprecedented overall response rate (ORR) in imatinib-resistant patients, with 46% of patients treated with the bezuclastinib combination achieving an objective response compared to 26% of patients treated with sunitinib. At the time of this analysis, data for overall survival remains immature.\u00a0<\/p>\n

The\u00a0bezuclastinib\u00a0combination was\u00a0generally well\u00a0tolerated, and no unique risks were\u00a0observed\u00a0with the novel combination when compared to the known safety profile of sunitinib.\u00a0<\/p>\n

The FDA\u2019s RTOR program allows an applicant to pre-submit components of its NDA to allow the FDA to review clinical trial data before the complete filing is\u00a0submitted\u00a0and aims to provide a more efficient review process to ensure safe and effective treatments are available to patients as early as possible. Cogent is expected to\u00a0initiate\u00a0the RTOR process\u00a0immediately\u00a0with\u00a0completion of the NDA\u00a0submission expected in April 2026.\u00a0<\/p>\n

Full results from the PEAK trial will be presented at a major medical meeting during the first half of 2026. Additionally,\u00a0Cogent\u00a0expects to\u00a0initiate\u00a0in mid-2026 a\u00a0Phase 2 trial investigating the benefit of the\u00a0bezuclastinib\u00a0combination for first-line GIST patients with exon 9 mutations\u00a0who are naive to, or recently\u00a0initiated\u00a0treatment with, imatinib.<\/p>\n

\n About Cogent Biosciences, Inc.<\/strong>
\n
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2\/3, ErbB2, PI3K\u03b1, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X<\/a> (formerly known as Twitter)\u00a0and\u00a0LinkedIn<\/a>. Information that may be important to investors will be routinely posted on our website and X<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the company\u2019s expectation that it will\u00a0initiate\u00a0the RTOR process\u00a0immediately\u00a0and complete its NDA submission for bezuclastinib in GIST in April 2026; the potential for the bezuclastinib\u00a0combination to\u00a0be the first approved therapy for GIST patients in over 20 years; plans to present the full results from the PEAK trial at a major medical meeting during the first half of 2026 and the expectation to initiate\u00a0in mid-2026 a\u00a0Phase 2 trial investigating the benefit of the\u00a0bezuclastinib\u00a0combination for first-line GIST patients with exon 9 mutations\u00a0who are naive to, or recently\u00a0initiated\u00a0treatment with, imatinib. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption “Risk Factors” in Cogent’s most recent Annual Report on Form 10-K and\/or Quarterly Report on Form 10-Q filed with the\u00a0SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.<\/p>\n

\n Contact:<\/strong>\n <\/p>\n

Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com<\/a>
617-830-1653<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

–\u00a0 PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and ORR of 46% in patients who had received prior treatment with imatinib\u00a0 –\u00a0 Cogent is expected to\u00a0initiate\u00a0the RTOR process\u00a0immediately;\u00a0completion of the PEAK NDA\u00a0submission expected in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc.\u202f(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has agreed to accept its New Drug Application (NDA) for bezuclastinib in combination with sunitinib for patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with … <\/p>\n

Continue reading “Cogent Biosciences to Initiate New Drug Application (NDA)\u00a0Submission for\u00a0Bezuclastinib Under\u00a0Real-Time Oncology Review (RTOR)\u00a0“<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-928588","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCogent Biosciences to Initiate New Drug Application (NDA)\u00a0Submission for\u00a0Bezuclastinib Under\u00a0Real-Time Oncology Review (RTOR)\u00a0 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cogent Biosciences to Initiate New Drug Application (NDA)\u00a0Submission for\u00a0Bezuclastinib Under\u00a0Real-Time Oncology Review (RTOR)\u00a0 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"–\u00a0 PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and ORR of 46% in patients who had received prior treatment with imatinib\u00a0 –\u00a0 Cogent is expected to\u00a0initiate\u00a0the RTOR process\u00a0immediately;\u00a0completion of the PEAK NDA\u00a0submission expected in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc.\u202f(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has agreed to accept its New Drug Application (NDA) for bezuclastinib in combination with sunitinib for patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with … Continue reading "Cogent Biosciences to Initiate New Drug Application (NDA)\u00a0Submission for\u00a0Bezuclastinib Under\u00a0Real-Time Oncology Review (RTOR)\u00a0"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-20T16:46:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyODE5NyM3MzY4ODU3IzIwODUxMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cogent Biosciences to Initiate New Drug Application (NDA)\u00a0Submission for\u00a0Bezuclastinib Under\u00a0Real-Time Oncology Review (RTOR)\u00a0\",\"datePublished\":\"2026-01-20T16:46:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\\\/\"},\"wordCount\":1052,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyODE5NyM3MzY4ODU3IzIwODUxMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\\\/\",\"name\":\"Cogent Biosciences to Initiate New Drug Application (NDA)\u00a0Submission for\u00a0Bezuclastinib Under\u00a0Real-Time Oncology Review (RTOR)\u00a0 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyODE5NyM3MzY4ODU3IzIwODUxMjc=\",\"datePublished\":\"2026-01-20T16:46:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyODE5NyM3MzY4ODU3IzIwODUxMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyODE5NyM3MzY4ODU3IzIwODUxMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cogent Biosciences to Initiate New Drug Application (NDA)\u00a0Submission for\u00a0Bezuclastinib Under\u00a0Real-Time Oncology Review (RTOR)\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cogent Biosciences to Initiate New Drug Application (NDA)\u00a0Submission for\u00a0Bezuclastinib Under\u00a0Real-Time Oncology Review (RTOR)\u00a0 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/","og_locale":"en_US","og_type":"article","og_title":"Cogent Biosciences to Initiate New Drug Application (NDA)\u00a0Submission for\u00a0Bezuclastinib Under\u00a0Real-Time Oncology Review (RTOR)\u00a0 - Market Newsdesk","og_description":"–\u00a0 PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and ORR of 46% in patients who had received prior treatment with imatinib\u00a0 –\u00a0 Cogent is expected to\u00a0initiate\u00a0the RTOR process\u00a0immediately;\u00a0completion of the PEAK NDA\u00a0submission expected in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc.\u202f(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has agreed to accept its New Drug Application (NDA) for bezuclastinib in combination with sunitinib for patients with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with … Continue reading \"Cogent Biosciences to Initiate New Drug Application (NDA)\u00a0Submission for\u00a0Bezuclastinib Under\u00a0Real-Time Oncology Review (RTOR)\u00a0\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-20T16:46:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyODE5NyM3MzY4ODU3IzIwODUxMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cogent Biosciences to Initiate New Drug Application (NDA)\u00a0Submission for\u00a0Bezuclastinib Under\u00a0Real-Time Oncology Review (RTOR)\u00a0","datePublished":"2026-01-20T16:46:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/"},"wordCount":1052,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyODE5NyM3MzY4ODU3IzIwODUxMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/","name":"Cogent Biosciences to Initiate New Drug Application (NDA)\u00a0Submission for\u00a0Bezuclastinib Under\u00a0Real-Time Oncology Review (RTOR)\u00a0 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyODE5NyM3MzY4ODU3IzIwODUxMjc=","datePublished":"2026-01-20T16:46:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyODE5NyM3MzY4ODU3IzIwODUxMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyODE5NyM3MzY4ODU3IzIwODUxMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cogent-biosciences-to-initiate-new-drug-application-nda-submission-for-bezuclastinib-under-real-time-oncology-review-rtor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cogent Biosciences to Initiate New Drug Application (NDA)\u00a0Submission for\u00a0Bezuclastinib Under\u00a0Real-Time Oncology Review (RTOR)\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/928588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=928588"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/928588\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=928588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=928588"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=928588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}